Copyright
©2013 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Obstet Gynecol. Nov 10, 2013; 2(4): 143-152
Published online Nov 10, 2013. doi: 10.5317/wjog.v2.i4.143
Published online Nov 10, 2013. doi: 10.5317/wjog.v2.i4.143
Pharmacology of cancer chemotherapy drugs for hyperthermic intraperitoneal peroperative chemotherapy in epithelial ovarian cancer
Kurt Van der Speeten, Department of Surgical Oncology, Ziekenhuis Oost-Limburg, 3600 Genk, Belgium
Kurt Van der Speeten, University Hasselt, Life Sciences Faculty, Oncology Research Cluster, 3000 Hasselt, Belgium
Anthony O Stuart, Paul H Sugarbaker, Washington Cancer Institute, Washington Hospital Center, Washington, DC 20010, United States
Author contributions: All authors contributed the data analysis and discussion of this review.
Correspondence to: Kurt Van der Speeten, MD, PhD, Department of Surgical Oncology, Ziekenhuis Oost-Limburg, Schiepse Bos 6, 3600 Genk, Belgium. kurt.vanderspeeten@zol.be
Telephone: +32-89-326524 Fax: +32-89-326524
Received: December 13, 2012
Revised: June 16, 2013
Accepted: June 23, 2013
Published online: November 10, 2013
Processing time: 339 Days and 5.4 Hours
Revised: June 16, 2013
Accepted: June 23, 2013
Published online: November 10, 2013
Processing time: 339 Days and 5.4 Hours
Core Tip
Core tip: Intraperitoneal (IP) chemotherapy is an important adjuvant treatment strategy in patients with advanced epithelial ovarian cancer. Although the clinical benefits have been demonstrated both in phase II and III trials, the pharmacologic rationale for this treatment strategy needs to be clarified. This manuscript reviews the pharmacokinetic and pharmacodynamic rationale of IP chemotherapy and analyzes the available data.